Long term efficacy, safety and tolerability (>24 Months) of twice daily dosing of deferasirox in transfusion dependent thalassemias who were unresponsive to standard once daily dose

Trial Profile

Long term efficacy, safety and tolerability (>24 Months) of twice daily dosing of deferasirox in transfusion dependent thalassemias who were unresponsive to standard once daily dose

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Thalassaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top